Skip to main content
Cellectis logo

Cellectis — Investor Relations & Filings

Ticker · ALCLS ISIN · FR0010425595 LEI · 5493000KKX5VQ37Q2W83 PA Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2026-05-20 Proxy Solicitation & In…
Country FR France
Listing PA ALCLS

About Cellectis

https://cellectis.com/en

Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.

Recent filings

Filing Released Lang Actions
L’Assemblée Générale Mixte de Cellectis se tiendra le le 25 juin 2026
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a press release announcing the date and venue of Cellectis’s Mixed General Meeting (Assemblée Générale Mixte) on June 25, 2026. It is not the meeting materials themselves, nor the results, but a notice sent to shareholders providing information about the meeting and to solicit attendance/votes. This fits the definition of a Proxy Solicitation & Information Statement (PSI) rather than an AGM presentation, voting result declaration, or regulatory fallback.
2026-05-20 French
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
AGM Information Classification · 80% confidence The document is a press release announcing the date, time, and venue for the company’s Annual General Meeting. It is not presenting financial results, proxy materials, or a full report—it is simply providing AGM logistics. This falls under the AGM Information category rather than a financial report or other regulatory filing.
2026-05-20 English
6-K
Regulatory Filings
2026-05-20 English
FORM 6-K
Regulatory Filings
2026-05-20 English
6-K - Cellectis S.A. (0001627281) (Filer)
Regulatory Filings
2026-05-12 English
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Regulatory Filings Classification · 40% confidence The document is a corporate press release announcing upcoming clinical data presentations at a scientific conference. It does not contain financial results, regulatory forms, management changes, or a formal report. It is not itself an investor slide deck, report publication announcement, or earnings release. Therefore it falls into the fallback “Regulatory Filings” category for miscellaneous announcements that do not fit other specific filing types.
2026-05-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.